Actively Recruiting
Angiotensin-(1-7) Cardiovascular Effects in Aging
Led by Milton S. Hershey Medical Center · Updated on 2025-09-19
26
Participants Needed
1
Research Sites
207 weeks
Total Duration
On this page
Sponsors
M
Milton S. Hershey Medical Center
Lead Sponsor
N
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.
CONDITIONS
Official Title
Angiotensin-(1-7) Cardiovascular Effects in Aging
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women of all races and ethnicities
- Able to give informed consent
- Fluent in written and spoken English
- Age between 65 and 80 years
- Body mass index between 18.5 and 30 kg/m2
- Normotensive with seated blood pressure below 130/80 mmHg and not taking hypertensive medications
- Satisfactory history and physical examination
You will not qualify if you...
- Age below 65 or above 80 years
- Women who are pregnant, nursing, or on hormone replacement therapy
- Decisional impairment
- Prisoners
- Current or recent (within 6 months) recreational drug use or excessive alcohol use (more than 14 drinks per week)
- Current smokers
- Highly trained athletes
- Diagnosis of type I or type II diabetes or use of anti-diabetic medications
- Hypertension or serious cardiovascular disease including recent myocardial infarction, symptomatic coronary artery disease, angina, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, advanced heart block, mitral or aortic stenosis, hypertrophic cardiomyopathy
- Cerebrovascular disease such as cerebral hemorrhage, stroke, or transient ischemic attack
- History or presence of immunological or hematological disorders
- Liver impairment with AST or ALT levels over twice the upper normal limit
- Kidney impairment with serum creatinine above 2.0 mg/dl
- Anemia
- Use of drugs affecting sympathetic activity such as serotonin-norepinephrine reuptake inhibitors, norepinephrine transporter inhibitors, stimulants
- Use of anticoagulants like warfarin
- Chronic systemic glucocorticoid therapy for more than 7 consecutive days in the past month
- Use of any investigational drug within the past month
- Known allergy or contraindication to ACE inhibitors or angiotensin receptor blockers
- Inability to give or withdrawal of informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States, 17033
Actively Recruiting
Research Team
A
Aimee Cauffman, RN
CONTACT
A
Amy Arnold, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here